Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

17/09/2018Race signs agreement with NSF Health Sciences to file INDDownload
13/09/2018Investor Presentation-Broker Meets Biotech ConferenceDownload
30/08/2018Appendix 3Y-Bill GarnerDownload
28/08/2018Appendix 3Y - Peter MolloyDownload
23/08/2018Management and services changes at Race OncologyDownload
21/08/2018Appendix 4GDownload
21/08/2018Appendix 4E & Financial StatementsDownload
03/08/2018Investor PresentationDownload
27/07/2018June 2018 Quarterly ReportDownload
18/07/2018FDA Grants Bisantrene Rare Paediatric Disease DesignationDownload
1  2  3  4  5  6  7  8  9  10  11  12  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2018 Race Oncology. Website By Multiplier